Intellia Therapeutics, Inc.
NTLA
$8.84
$0.202.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 41.30% | 30.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 41.30% | 30.96% | |||
| Cost of Revenue | -5.27% | 8.03% | |||
| Gross Profit | 8.98% | -6.54% | |||
| SG&A Expenses | 6.37% | -4.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.96% | 5.40% | |||
| Operating Income | 5.75% | -4.12% | |||
| Income Before Tax | 5.02% | 7.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.02% | 7.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.02% | 7.66% | |||
| EBIT | 5.75% | -4.12% | |||
| EBITDA | 5.83% | -4.19% | |||
| EPS Basic | 5.82% | 11.34% | |||
| Normalized Basic EPS | 5.95% | -0.58% | |||
| EPS Diluted | 5.82% | 11.34% | |||
| Normalized Diluted EPS | 5.95% | -0.58% | |||
| Average Basic Shares Outstanding | 0.84% | 4.15% | |||
| Average Diluted Shares Outstanding | 0.84% | 4.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||